These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 38450559)
41. Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma. Beaino W; Nedrow JR; Anderson CJ Mol Pharm; 2015 Jun; 12(6):1929-38. PubMed ID: 25919487 [TBL] [Abstract][Full Text] [Related]
42. Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [ Doot RK; Young AJ; Daube-Witherspoon ME; Alexoff D; Labban KJ; Lee H; Wu Z; Zha Z; Choi SR; Ploessl KH; Schubert EK; Lee H; Zhu L; Reddin JS; Karp JS; Kung H; Pryma DA Nucl Med Biol; 2020; 86-87():1-8. PubMed ID: 32361089 [TBL] [Abstract][Full Text] [Related]
43. In vivo comparison of DOTA based 68Ga-labelled bisphosphonates for bone imaging in non-tumour models. Meckel M; Fellner M; Thieme N; Bergmann R; Kubicek V; Rösch F Nucl Med Biol; 2013 Aug; 40(6):823-30. PubMed ID: 23915801 [TBL] [Abstract][Full Text] [Related]
44. Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-α-targeted radiotheranostic for cancer imaging and therapy. Bendre S; Merkens H; Kuo HT; Ng P; Wong AAWL; Lau WS; Zhang Z; Kurkowska S; Chen CC; Uribe C; Bénard F; Lin KS Eur J Med Chem; 2024 Mar; 268():116238. PubMed ID: 38367492 [TBL] [Abstract][Full Text] [Related]
46. (68)Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter. Fellner M; Biesalski B; Bausbacher N; Kubícek V; Hermann P; Rösch F; Thews O Nucl Med Biol; 2012 Oct; 39(7):993-9. PubMed ID: 22633217 [TBL] [Abstract][Full Text] [Related]
47. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121 [TBL] [Abstract][Full Text] [Related]
48. The inferior performance of [ Has Simsek D; Guzel Y; Denizmen D; Sanli Y; Buyukkaya F; Kovan B; Komek H; Isik EG; Ozkan ZG; Kuyumcu S Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):828-840. PubMed ID: 37947850 [TBL] [Abstract][Full Text] [Related]
49. Lutetium177-Labeled DOTA-Ibandronate: A Novel Radiopharmaceutical for Targeted Treatment of Bone Metastases. Wang Q; Yang J; Wang Y; Liu H; Feng Y; Qiu L; Chen Y Mol Pharm; 2023 Mar; 20(3):1788-1795. PubMed ID: 36802692 [TBL] [Abstract][Full Text] [Related]
50. A theranostic approach of [ Ballal S; Yadav MP; Kramer V; Moon ES; Roesch F; Tripathi M; Mallick S; ArunRaj ST; Bal C Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):942-944. PubMed ID: 32783111 [No Abstract] [Full Text] [Related]
51. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions. Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316 [TBL] [Abstract][Full Text] [Related]
52. The role of Ga Erdogan M; Sengul SS; Cetin B; Avcı M; Yagci S; Ozkoç I; Barikan DE; Yildiz M Ann Nucl Med; 2022 Jun; 36(6):562-569. PubMed ID: 35397091 [TBL] [Abstract][Full Text] [Related]
54. Evaluation of Zhang Q; Liu T; Ding J; Zhou N; Yu Z; Ren Y; Qin X; Du P; Yang Z; Zhu H Mol Pharm; 2022 Nov; 19(11):4149-4156. PubMed ID: 36198565 [TBL] [Abstract][Full Text] [Related]
55. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298 [TBL] [Abstract][Full Text] [Related]
56. Synthesis and evaluation of a novel urea-based Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281 [TBL] [Abstract][Full Text] [Related]
59. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy. Zhao L; Chen J; Pang Y; Fang J; Fu K; Meng L; Zhang X; Guo Z; Wu H; Sun L; Su G; Lin Q; Chen H Mol Pharm; 2022 Oct; 19(10):3640-3651. PubMed ID: 35917335 [TBL] [Abstract][Full Text] [Related]
60. Radiogallium Complex-Conjugated Bifunctional Peptides for Detecting Primary Cancer and Bone Metastases Simultaneously. Ogawa K; Yu J; Ishizaki A; Yokokawa M; Kitamura M; Kitamura Y; Shiba K; Odani A Bioconjug Chem; 2015 Aug; 26(8):1561-70. PubMed ID: 26087328 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]